Semaglutid: -8,3% Gewichtsverlust 82% der Tirzepatid-Patienten erreichten 5% Gewichtsverlust (51% 15%) 67% der Semaglutid-Patienten erreichten 5% Gewichtsverlust (26% 15%) Wichtiger Hinweis zur Therapietreue: ber die Hlfte (54%) der Patienten brachen die Therapie innerhalb von 12 Monaten ab sei es durch Nebenwirkungen, Kosten oder begrenzte Verfgbarkeit
Moreover, in patients with ED, particularly in middle-aged and elderly patients, dynamic PDU may also provide a predictive response for the potential effectiveness of the vasodilative drugs used for ED, as demonstrated by the negative correlation between the severity of penile vascular damage and the clinical response to treatment with PDE5i [38]
Exclusion criteria included previous participation in this study, treatment with an investigational drug 30 days prior to enrolment, mental incapacity, and unwillingness or language barriers preventing understanding or cooperation
Balasubramanian, N., Hao, Y.-J., Toubarro, D., Nascimento, G
